Nebenwirkungen · Lynparza
Lynparza 100 mg film-coated tablets Lynparza 150 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 16
HOS-130537 · Präparat HOS-096931
Pure Red Cell Aplasia Pure Red Cell Aplasia (PRCA) has been reported when Lynparza has been used in combination with durvalumab. In a clinical study of patients with endometrial cancer treated with Lynparza in combination with durvalumab, the incidence of PRCA was 1.6%. All events were CTCAE Grade 3 or 4. Events were manageable following discontinuation of both Lynparza and durvalumab. The majority of events were managed with blood transfusion and immunosuppression and recovered; there were no fatal events. For risk mitigation and management see section 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-19T16:20:00Z · SHA-256 04cb6a8e4fff66099a345e60858378068000de050b0e7fedaddb3d5347849598 · Passage e07e4b8b47ca17113e58684b23e970925ba069545482d0767988543a0a79d9dc · Zeichen 15378–15942 im Abschnitt